Choosing SCIg Over IVIg

SCIg vs IVIg: Differences between routes of administration

IVIgSCIg
WhoInfusion usually performed by an HCPInfusion can be performed by patients or caregivers after training
WhereIs usually performed in a healthcare facilityOnce trained, treament almost anywhere (home, office, travel)

Studies have demonstrated that SCIg delivery is feasible, safe, efficient and cost-effective1-4

SCIg infusions have steadily replaced IVIg infusions1

Many patients prefer SCIg for multiple reasons:1-4

Icon of a houseHome

Icon of a schoolSchool

Icon of person working at deskOffice/Work

Icon of suitcaseTravel

  • Ability to self-administer or administration by the patients’ caregiver after training almost anywhere: home, school, office, work, travel, etc.
  • Allows greater freedom and convenience
  • Minimal impact on family, work, and school activities
  • Removes the need to travel to infusion clinics or hospital

Cutaquig allows patients to comfortably switch from IVIg to SCIg, enabling the transition to home care.5

IVIg vs SCIg Infusion: Concentrations over time

SCIg treatment provides stable serum immunoglobulin levels6

  • Traditionally, maintenance replacement SCIg therapy is preceded by a switch from existing IVIg therapy
  • In most cases, the first SCIg infusion is given 1 week after the last IVIg infusion in order to maintain high serum immunoglobulin levels
  • Thereafter, the average daily immunoglobulin level achieved with IVIg can be maintained with regular subcutaneous infusions

Serum immunoglobulin levels achieved with IVIg and/or SCIg administration6

Serum IgG Concentration Graph

Jolles S, Stein MR, Longhurst HJ et al. Biol Therapy. 2011; 1: 3. https://doi.org/10.1007/s13554-011-0009-3

Learn more about the ease of administration and pharmacokinetics of cutaquig.

Learn more

References:
  1. Kobayashi RH, Gupta S, Melamed I, et al. Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (octanorm [cutaquig®]) in the Treatment of Patients with Primary Immunodeficiencies. Front Immunol. February 2019 | Volume 10 | Article 40.
  2. McCormack PL. Immune Globulin Subcutaneous (Human) 20% In Primary Immunodeficiency Disorders. Drugs. 2012; 72 (8): 1087-1097.
  3. Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics: Targets and Therapy.2012:6 277–287.
  4. Berman K. Safety, Efficacy, Tolerability, Advantages and Disadvantages of Intravenous and Subcutaneous Immune Globulin Therapy. Highlights from IG Living Teleconference December 10, 2015. http://www.igliving.com/life-with-ig/teleconference/advantages-and-disadvantages-of-intravenous-and-subcutaneous-immune-globulin-therapy.html.
  5. Data on file, Octaphama.
  6. Jolles S, Stein MR, Longhurst HJ et al. New Frontiers in Subcutaneous Immunoglobulin Treatment. Biol Therapy. 2011; 1: 3. https://doi.org/10.1007/s13554-011-0009-3.